OTTAWA, Sept. 20, 2011 /CNW/ - Public opinion poll results released
today show that Canadians believe that investment in innovative
vaccines and medicines not only improve health outcomes, but contribute
to a sustainable health care system and a stronger economy.
Conducted in July and early August 2011 the public opinion survey by
Nanos Research of 1200 Canadians shows that 93% of respondents agree or
somewhat agree that new medicines and vaccines improve the quality of
life of patients.
A majority of Canadians (80%) agree or somewhat agree that new medicines
and vaccines reduce costs to the health care system by reducing
hospital surgeries and admissions. Over eight in ten Canadians (84%)
agree or somewhat agree that public vaccination programs, increase
general productivity in the workplace by reducing sickness and
Finally, 90% of respondents agree or somewhat agree that vaccines have
the potential to save lives by addressing major public health threats.
"These results demonstrate that Canadians understand the full value
brought by innovative medicines and vaccines," said Russell Williams,
President of Rx&D Canada. "Canadians see the potential of vaccination
programs and the role they play in terms of positive health care
outcomes, savings and sustainability."
Vaccines are considered one of the most effective health interventions
ever developed in the fight against disease. Many diseases are now
vaccine preventable and each year vaccines save an estimated three
million lives world-wide.
"The high value Canadians place on vaccines is well earned due to the
role they play in keeping Canadians healthy, from preventing infectious
diseases such as polio and mumps to the recent H1N1 influenza pandemic.
This is why governments fund vaccination programs," said Mark Lievonen,
Co-Chair of the Vaccine Industry Committee.
"Canada has been a leader in vaccines research and development, and we
need to maintain that leadership position," declared Russell Williams.
"It is crucial that Canada supports strong and internationally
competitive intellectual property safeguards, as contemplated by the
on-going CETA negotiations with the European Union, so that research is
performed in our country and we make the best use of our scientific and
"It is critical that governments adopt policies that recognize the costs
associated with developing innovative vaccines and the value they
bring, not only to our health care system but our entire economy. With
the right approach, we can provide greater hope for future
Nanos Research conducted a national random telephone survey of 1,203
Canadians between July 25th and August 2nd, 2011. The margin of error
for a survey of 1,203 Canadians is ± 2.8 percentage points 19 times out
The results of the National Nanos Research poll can be found at www.canadapharma.org.
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information:
Telephone: 613-236-0455 Ext. 831
Cell: 613 863-2120